Advertisement

Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 600x80px
Document › Details

AstraZeneca plc. (8/17/17). "Press Release: Lynparza Receives Additional and Broad Approval in the US for Ovarian Cancer".

Region Region United States (USA)
Organisations Organisation AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
  Organisation 2 FDA (US Food and Drug Administration)
  Group United States (govt)
Products Product Lynparza®
  Product 2 chemotherapeutic
Index term Index term AstraZeneca–Merck (US): cancer drugs, 201707– strategic oncology collab maximising combis of PARP + MEK inhibitors with PD-L1/PD1 medicines
Persons Person Bohen, Sean (AstraZeneca 201509– EVP Global Medicines Developent + CMO before Genentech + Stanford Univ)
  Person 2 Perlmutter, Roger M. (Merck (US) 2013– EVP + President of Merck Research Labs before Amgen 2001–2012)
     


   
Record changed: 2017-08-24

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for AstraZeneca (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 120x180px